 Chronic therapy congestive heart failure benazepril HCl new angiotensin enzyme inhibitor Benazepril HCl effective angiotensin enzyme ACE inhibitor significant acute hemodynamic benefits patients congestive heart failure study patients New York Heart Association Class III IV congestive heart failure mg benazepril HCl single daily oral dose days clinical hemodynamic value chronic therapy patient underwent clinical evaluation period invasive hemodynamic studies first last days trial Plasma ACE activity aldosterone levels renin levels therapy Benazepril HCl significant reductions arterial pressure systemic vascular resistance corresponding increases cardiac output decreases pulmonary artery wedge pressure Responses days therapy equivalent initial doses Clinical effects reduced rest exertional paroxysmal nocturnal dyspnea peripheral edema patient symptomatic orthostatic hypotension benazepril HCl daily effective tolerated oral agent chronic treatment advanced congestive heart failure